Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Cash & Current Investments: 2009-2024

Historic Cash & Current Investments for Cytokinetics (CYTK) over the last 16 years, with Dec 2024 value amounting to $1.1 billion.

  • Cytokinetics' Cash & Current Investments fell 4.89% to $962.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 billion, marking a year-over-year increase of 16.08%. This contributed to the annual value of $1.1 billion for FY2024, which is 74.91% up from last year.
  • Cytokinetics' Cash & Current Investments amounted to $1.1 billion in FY2024, which was up 74.91% from $615.2 million recorded in FY2023.
  • In the past 5 years, Cytokinetics' Cash & Current Investments ranged from a high of $1.1 billion in FY2024 and a low of $464.1 million during FY2020.
  • For the 3-year period, Cytokinetics' Cash & Current Investments averaged around $825.1 million, with its median value being $784.2 million (2022).
  • Its Cash & Current Investments has fluctuated over the past 5 years, first soared by 106.15% in 2020, then decreased by 21.55% in 2023.
  • Cytokinetics' Cash & Current Investments (Yearly) stood at $464.1 million in 2020, then grew by 1.63% to $471.6 million in 2021, then surged by 66.27% to $784.2 million in 2022, then decreased by 21.55% to $615.2 million in 2023, then soared by 74.91% to $1.1 billion in 2024.